GH Research PLC Files 6-K, Updates GH001 Trial
Ticker: GHRS · Form: 6-K · Filed: Jan 31, 2025 · CIK: 1855129
Sentiment: neutral
Topics: clinical-trial, pharmaceutical, filing-update
TL;DR
GH Research 6-K: Phase 2b trial update for GH001 released Jan 31.
AI Summary
GH Research PLC filed a 6-K report on January 31, 2025, announcing an update on its Phase 2b trial for GH001. The company, headquartered in Dublin, Ireland, is involved in the pharmaceutical preparations industry.
Why It Matters
This filing indicates ongoing clinical trial progress for GH001, which could impact the future development and potential market presence of the drug.
Risk Assessment
Risk Level: medium — Clinical trial updates can introduce volatility based on trial results and future prospects.
Key Players & Entities
- GH Research PLC (company) — Registrant
- GH001 (drug) — Subject of Phase 2b trial
- Julie Ryan (person) — Vice President, Finance
- January 31, 2025 (date) — Filing and press release date
FAQ
What is the specific update provided regarding the Phase 2b trial of GH001?
The filing indicates that GH Research PLC will provide an update on its Phase 2b trial with GH001, as detailed in the press release dated January 31, 2025 (Exhibit 99.1).
What is the primary business of GH Research PLC?
GH Research PLC is classified under Pharmaceutical Preparations [2834].
Where is GH Research PLC's principal executive office located?
The principal executive office is located at Joshua Dawson House, Dawson Street, Dublin 2, D02 RY95, Ireland.
Who signed the 6-K report on behalf of GH Research PLC?
The report was signed by Julie Ryan, Vice President, Finance.
What is the SEC file number for GH Research PLC?
The SEC file number for GH Research PLC is 001-40530.
Filing Stats: 152 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2025-01-31 16:07:13
Filing Documents
- dp224182_6k.htm (6-K) — 8KB
- dp224182_ex9901.htm (EX-99.1) — 5KB
- 0000950103-25-001275.txt ( ) — 15KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2025. Commission File Number: 001-40530 GH Research PLC (Exact name of registrant as specified in its charter) Joshua Dawson House Dawson Street Dublin 2 D02 RY95 Ireland (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F EXHIBIT INDEX Exhibit No. Description 99.1 Press release dated January 31, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. GH Research PLC Date: January 31, 2025 By: /s/ Julie Ryan Name: Julie Ryan Title: Vice President, Finance